Table of Content

Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL FREE FATTY ACID RECEPTOR 4 INDUSTRY
2.1 Summary about Free Fatty Acid Receptor 4 Industry
2.2 Free Fatty Acid Receptor 4 Market Trends
2.2.1 Free Fatty Acid Receptor 4 Production & Consumption Trends
2.2.2 Free Fatty Acid Receptor 4 Demand Structure Trends
2.3 Free Fatty Acid Receptor 4 Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 CB-001
4.2.2 GSK-137647A
4.2.3 SC-410
4.2.4 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Non Alcoholic Fatty Liver Disease
4.3.2 Type 2 Diabets
4.3.3 Metabolic Disorders
4.3.4 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 CB-001
5.2.2 GSK-137647A
5.2.3 SC-410
5.2.4 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Non Alcoholic Fatty Liver Disease
5.3.2 Type 2 Diabets
5.3.3 Metabolic Disorders
5.3.4 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 CB-001
6.2.2 GSK-137647A
6.2.3 SC-410
6.2.4 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Non Alcoholic Fatty Liver Disease
6.3.2 Type 2 Diabets
6.3.3 Metabolic Disorders
6.3.4 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 CB-001
7.2.2 GSK-137647A
7.2.3 SC-410
7.2.4 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Non Alcoholic Fatty Liver Disease
7.3.2 Type 2 Diabets
7.3.3 Metabolic Disorders
7.3.4 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 CB-001
8.2.2 GSK-137647A
8.2.3 SC-410
8.2.4 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Non Alcoholic Fatty Liver Disease
8.3.2 Type 2 Diabets
8.3.3 Metabolic Disorders
8.3.4 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 CB-001
9.2.2 GSK-137647A
9.2.3 SC-410
9.2.4 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Non Alcoholic Fatty Liver Disease
9.3.2 Type 2 Diabets
9.3.3 Metabolic Disorders
9.3.4 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Advinus Therapeutics Ltd
10.1.2 AstraZeneca Plc
10.1.3 CymaBay Therapeutics Inc
10.1.4 Dompe Farmaceutici SpA
10.1.5 GlaxoSmithKline Plc
10.1.6 Merck & Co Inc
10.1.7 Sancilio & Company Inc
10.2 Free Fatty Acid Receptor 4 Sales Date of Major Players (2017-2020e)
10.2.1 Advinus Therapeutics Ltd
10.2.2 AstraZeneca Plc
10.2.3 CymaBay Therapeutics Inc
10.2.4 Dompe Farmaceutici SpA
10.2.5 GlaxoSmithKline Plc
10.2.6 Merck & Co Inc
10.2.7 Sancilio & Company Inc
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

List of Figure

List of Table
Table Free Fatty Acid Receptor 4 Product Type Overview
Table Free Fatty Acid Receptor 4 Product Type Market Share List
Table Free Fatty Acid Receptor 4 Product Type of Major Players
Table Brief Introduction of Advinus Therapeutics Ltd
Table Brief Introduction of AstraZeneca Plc
Table Brief Introduction of CymaBay Therapeutics Inc
Table Brief Introduction of Dompe Farmaceutici SpA
Table Brief Introduction of GlaxoSmithKline Plc
Table Brief Introduction of Merck & Co Inc
Table Brief Introduction of Sancilio & Company Inc
Table Products & Services of Advinus Therapeutics Ltd
Table Products & Services of AstraZeneca Plc
Table Products & Services of CymaBay Therapeutics Inc
Table Products & Services of Dompe Farmaceutici SpA
Table Products & Services of GlaxoSmithKline Plc
Table Products & Services of Merck & Co Inc
Table Products & Services of Sancilio & Company Inc
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Free Fatty Acid Receptor 4 Market Forecast (Million USD) by Region 2021f-2026f
Table Global Free Fatty Acid Receptor 4 Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Free Fatty Acid Receptor 4 Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Free Fatty Acid Receptor 4 Market Forecast (Million USD) Share by Demand 2021f-2026f